Allos Therapeutics to Present at the Needham & Company Biotechnology Conference
19 Maio 2005 - 10:00AM
PR Newswire (US)
Allos Therapeutics to Present at the Needham & Company
Biotechnology Conference WESTMINSTER, Colo., May 19
/PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH)
today announced that the Company will participate in Needham &
Company's 2005 Biotechnology Conference, to be held May 25 - 26 in
New York City. Michael E. Hart, the Company's President and Chief
Executive Officer, will give a 30-minute corporate overview on
Thursday, May 26 at 11:00 AM ET. The presentation will be webcast
live and may be accessed by visiting the Allos website at
http://www.allos.com/. A replay of the webcast will also be
available on the company's website until Friday, June 10, 2005.
About Allos Therapeutics, Inc. Allos Therapeutics, Inc.
(NASDAQ:ALTH) is a biopharmaceutical company focused on developing
and commercializing innovative small molecule therapeutics for the
treatment of cancer. Our lead product candidate, EFAPROXYN(TM)
(efaproxiral), is a synthetic small molecule designed to sensitize
hypoxic, or oxygen-deprived, tumor tissue during radiation therapy.
EFAPROXYN is currently being evaluated as an adjunct to whole brain
radiation therapy in a pivotal Phase 3 trial in women with brain
metastases originating from breast cancer. Our other product
candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy
regimens in patients with non-small cell lung cancer and
Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic
agent bioactivated by the enzyme DT-diaphorase currently under
evaluation in patients with advanced solid tumors. For more
information, please visit the company's web site at:
http://www.allos.com/. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K/A for the year
ended December 31, 2004 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics - Common Stock (MM)